Home Hemodialysis Revenue and Competitors
Estimated Revenue & Valuation
- Home Hemodialysis's estimated annual revenue is currently $5.3M per year.
- Home Hemodialysis's estimated revenue per employee is $251,000
Employee Data
- Home Hemodialysis has 21 Employees.
- Home Hemodialysis grew their employee count by 11% last year.
Home Hemodialysis's People
| Name | Title | Email/Phone |
|---|
Home Hemodialysis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Home Hemodialysis?
NextKidney's mission is to develop and commercialize the Neokidney home hemodialysis device. Placing the patient and his quality of life at the center of its approach, the company uses innovative technologies to offer a safe, practical and easy-to-use solution as quickly as and widely as possible throughout the world.
keywords:N/A
N/A
Total Funding
21
Number of Employees
$5.3M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Home Hemodialysis News
Doing hemodialysis at home has become an effective solution for patients with kidney failure during the current lockdown.
There are two types of dialysis, peritoneal dialysis and home hemodialysis, Adam Boehler, CEO of Rubicon Founders, told Home Health Care...
Outset Medical Presents New Data on Home Dialysis at National Kidney Foundation Spring Meetings. Findings Show Tablo® Hemodialysis System...
Other Companies in Lausanne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.6M | 21 | -22% | N/A |
#2 | $3.3M | 21 | 0% | N/A |
#3 | $3.2M | 21 | -30% | N/A |
#4 | $2.3M | 23 | -26% | N/A |
#5 | $3.4M | 23 | 21% | N/A |